Jan. 11 Quick Takes: Megarounds for Valo, Visen; plus NuProbe, Sensei
Flagship re-ups in $190M series B for Valo
Valo Health LLC raised $190 million in a series B round, bringing its total capital raised to $285 million. The Public Sector Pension Investment Board (PSP Investments) led the round, joined by Flagship Pioneering and other existing investors plus new institutional investors including Invus Public Equities, HBM Healthcare Investments, Atinum Investment and Mirae Asset Capital. The vintage 2019 Boston-based company debuted in September with a cloud-computing platform that is geared to guide everything from target discovery to clinical trial design.
Visen raises $150M to support endocrinology-focused pipeline
Visen Pharmaceuticals raised $150 million in a series B round to support development of its endocrinology therapies in Greater China. Sequoia China led the round with participation from OrbiMed Advisors, Sherpa Healthcare Partners, Cormorant, HBM Healthcare Investments, Pivotal bioVenture Partners China, Logos Capital and CDG Capital. All of the company’s existing investors participated, including Ascendis Pharma A/S (NASDAQ:ASND), Vivo Capital and Sofinnova Investments. Led by CEO Pony Lu, the company has China rights to multiple TransCon endocrinology product candidates from Ascendis...